Moderna (MRNA) had the lowest return last year by a US stock in the Biotechnology Industry and the S&P 500 (GSPC), returning -58.4%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Moderna (MRNA) | 2024 | -58.37% |
Biogen (BIIB) | 2024 | -40.63% |
Regeneron Pharmaceuticals (REGN) | 2024 | -18.49% |
Amgen (AMGN) | 2024 | -6.53% |
Vertex Pharmaceuticals (VRTX) | 2024 | -0.57% |
Incyte (INCY) | 2024 | 10.71% |
Gilead Sciences (GILD) | 2024 | 18.83% |
AbbVie (ABBV) | 2024 | 18.92% |
